Search results (1320)
« Back to PublicationsHealth-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM. et al, (2003), Cancer Invest, 21, 821 - 829
Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.
Middleton MR. and Margison GP., (2003), Lancet Oncol, 4, 37 - 44
Brain metastases in melanoma: a European perspective.
Cattell E. et al, (2002), Semin Oncol, 29, 513 - 517
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Corrie P. et al, (2002), Br J Cancer, 87, 716 - 719
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Middleton MR. et al, (2002), Int J Cancer, 100, 615 - 617
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
Middleton M. et al, (2002), J Clin Pharmacol, 42, 774 - 781
Assessing outcomes in palliative chemotherapy.
Cattell E. et al, (2002), Expert Opin Pharmacother, 3, 693 - 700
Toxicity of temozolomide with response modifiers in metastatic malignant melanoma
Lorigan P. et al, (2002), BRITISH JOURNAL OF CANCER, 86, S68 - S68
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Paul MJ. et al, (2002), Melanoma Res, 12, 175 - 178
The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours.
Blagden SP. et al, (2002), Br J Cancer, 86, 26 - 30
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.
White SC. et al, (2001), Cancer, 92, 601 - 608
Temozolomide: a novel oral alkylating agent.
Danson SJ. and Middleton MR., (2001), Expert Rev Anticancer Ther, 1, 13 - 19
Adjuvant interferon in melanoma - a resurrection?
Middleton MR. and Thatcher N., (2001), Br J Cancer, 84, 1141 - 1142
O-6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of phase II study
Middleton MR. et al, (2000), INTERNATIONAL JOURNAL OF CANCER, 88, 469 - 473
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR. et al, (2000), Int J Cancer, 88, 469 - 473
O6‐methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study
Middleton MR. et al, (2000), International Journal of Cancer, 88, 469 - 473
Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide
Middleton MR. et al, (2000), CLINICAL CANCER RESEARCH, 6, 4574S - 4574S
Adjuvant interferon in the treatment of melanoma - Reply
Middleton MR., (2000), BRITISH JOURNAL OF CANCER, 82, 1755 - 1756
Temozolomide for advanced, metastatic melanoma - Reply
Middleton MR., (2000), JOURNAL OF CLINICAL ONCOLOGY, 18, 2185 - 2185